These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
344 related articles for article (PubMed ID: 28391386)
1. Assessment of prognostic scores of brain metastases from lung adenocarcinoma with EGFR mutations. Li H; Lian J; Jin H; Wang W; Cao J; Zhang X; Song X; Jia S; Jia H; Ren J; Han S; Yang W; Xi Y; Lan S J Neurooncol; 2017 May; 133(1):129-135. PubMed ID: 28391386 [TBL] [Abstract][Full Text] [Related]
2. Impacts of EGFR-mutation status and EGFR-TKI on the efficacy of stereotactic radiosurgery for brain metastases from non-small cell lung adenocarcinoma: A retrospective analysis of 133 consecutive patients. Yomo S; Oda K Lung Cancer; 2018 May; 119():120-126. PubMed ID: 29656746 [TBL] [Abstract][Full Text] [Related]
3. Additional prognostic role of EGFR activating mutations in lung adenocarcinoma patients with brain metastasis: integrating with lung specific GPA score. Lee DW; Shin DY; Kim JW; Keam B; Kim TM; Kim HJ; Kim DW; Wu HG; Paek SH; Kim YW; Heo DS; Kim DG; Lee SH Lung Cancer; 2014 Dec; 86(3):363-8. PubMed ID: 25453849 [TBL] [Abstract][Full Text] [Related]
4. A retrospective analysis in patients with EGFR-mutant lung adenocarcinoma: is EGFR mutation associated with a higher incidence of brain metastasis? Han G; Bi J; Tan W; Wei X; Wang X; Ying X; Guo X; Zhou X; Hu D; Zhen W Oncotarget; 2016 Aug; 7(35):56998-57010. PubMed ID: 27486770 [TBL] [Abstract][Full Text] [Related]
5. Impact of epidermal growth factor receptor mutations on intracranial treatment response and survival after brain metastases in lung adenocarcinoma patients. Hsiao SH; Lin HC; Chou YT; Lin SE; Kuo CC; Yu MC; Chung CL Lung Cancer; 2013 Sep; 81(3):455-461. PubMed ID: 23871711 [TBL] [Abstract][Full Text] [Related]
6. Risk factors of brain metastasis during the course of EGFR-TKIs therapy for patients with EGFR-mutated advanced lung adenocarcinoma. Ma X; Zhu H; Guo H; Han A; Wang H; Jing W; Zhang Y; Kong L; Yu J Oncotarget; 2016 Dec; 7(49):81906-81917. PubMed ID: 27626317 [TBL] [Abstract][Full Text] [Related]
8. A study on different therapies and prognosis-related factors for brain metastases in lung adenocarcinoma patients with driver mutation. Yang H; He D; Wang F; Deng Q; Xie Z Clin Exp Metastasis; 2020 Jun; 37(3):391-399. PubMed ID: 32356218 [TBL] [Abstract][Full Text] [Related]
9. Prognostic model for brain metastases from lung adenocarcinoma identified with epidermal growth factor receptor mutation status. Li H; Wang W; Jia H; Lian J; Cao J; Zhang X; Song X; Jia S; Li Z; Cao X; Zhou W; Han S; Yang W; Xi Y; Lian S Thorac Cancer; 2017 Sep; 8(5):436-442. PubMed ID: 28597503 [TBL] [Abstract][Full Text] [Related]
10. New prognostic system specific for epidermal growth factor receptor-mutated lung cancer brain metastasis. Zhu LH; Fan XW; Sun L; Ni TT; Li YQ; Wu CY; Wu KL Front Oncol; 2023; 13():1093084. PubMed ID: 37020869 [TBL] [Abstract][Full Text] [Related]
11. First-line epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor alone or with whole-brain radiotherapy for brain metastases in patients with EGFR-mutated lung adenocarcinoma. Chen Y; Yang J; Li X; Hao D; Wu X; Yang Y; He C; Wang W; Wang J Cancer Sci; 2016 Dec; 107(12):1800-1805. PubMed ID: 27627582 [TBL] [Abstract][Full Text] [Related]
12. Prognostic indices in stereotactic radiotherapy of brain metastases of non-small cell lung cancer. Kaul D; Angelidis A; Budach V; Ghadjar P; Kufeld M; Badakhshi H Radiat Oncol; 2015 Nov; 10():244. PubMed ID: 26611493 [TBL] [Abstract][Full Text] [Related]
13. Estimating Survival in Patients With Lung Cancer and Brain Metastases: An Update of the Graded Prognostic Assessment for Lung Cancer Using Molecular Markers (Lung-molGPA). Sperduto PW; Yang TJ; Beal K; Pan H; Brown PD; Bangdiwala A; Shanley R; Yeh N; Gaspar LE; Braunstein S; Sneed P; Boyle J; Kirkpatrick JP; Mak KS; Shih HA; Engelman A; Roberge D; Arvold ND; Alexander B; Awad MM; Contessa J; Chiang V; Hardie J; Ma D; Lou E; Sperduto W; Mehta MP JAMA Oncol; 2017 Jun; 3(6):827-831. PubMed ID: 27892978 [TBL] [Abstract][Full Text] [Related]
14. Skeletal-related events in advanced lung adenocarcinoma patients evaluated EGFR mutations. Nagata M; Kudoh S; Mitsuoka S; Suzumura T; Umekawa K; Tanaka H; Matsuura K; Kimura T; Yoshimura N; Hirata K Osaka City Med J; 2013 Jun; 59(1):45-52. PubMed ID: 23909080 [TBL] [Abstract][Full Text] [Related]
15. Bevacizumab improved prognosis for advanced EGFR-mutant lung adenocarcinoma with brain metastasis receiving cerebral radiotherapy. Zhou Y; Li J; Li Y; Deng G; Wang Q; Qin H; Li J; Li Z Clin Transl Oncol; 2024 Aug; 26(8):1968-1975. PubMed ID: 38478262 [TBL] [Abstract][Full Text] [Related]
16. Combination therapy of brain radiotherapy and EGFR-TKIs is more effective than TKIs alone for EGFR-mutant lung adenocarcinoma patients with asymptomatic brain metastasis. Chen Y; Wei J; Cai J; Liu A BMC Cancer; 2019 Aug; 19(1):793. PubMed ID: 31399067 [TBL] [Abstract][Full Text] [Related]
17. Therapeutic Effect of First-line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) Combined with Whole Brain Radiotherapy on Patients with EGFR Mutation-positive Lung Adenocarcinoma and Brain Metastases. Ke SB; Qiu H; Chen JM; Shi W; Chen YS Curr Med Sci; 2018 Dec; 38(6):1062-1068. PubMed ID: 30536070 [TBL] [Abstract][Full Text] [Related]
18. Monitoring of cyclooxygenase-2 levels can predict EGFR mutations and the efficacy of EGFR-TKI in patients with lung adenocarcinoma. Li H; Wang Y; Su F; Li J; Gong P Int J Clin Exp Pathol; 2015; 8(5):5577-83. PubMed ID: 26191267 [TBL] [Abstract][Full Text] [Related]
19. Radiotherapy for asymptomatic brain metastasis in epidermal growth factor receptor mutant non-small cell lung cancer without prior tyrosine kinase inhibitors treatment: a retrospective clinical study. Liu S; Qiu B; Chen L; Wang F; Liang Y; Cai P; Zhang L; Chen Z; Liu S; Liu M; Liu H Radiat Oncol; 2015 May; 10():118. PubMed ID: 26014133 [TBL] [Abstract][Full Text] [Related]
20. Applicability of graded prognostic assessment of lung cancer using molecular markers to lung adenocarcinoma patients with brain metastases. Li H; Lian J; Han S; Wang W; Jia H; Cao J; Zhang X; Song X; Jia S; Ren J; Yang W; Xi Y; Lan S Oncotarget; 2017 Sep; 8(41):70727-70735. PubMed ID: 29050314 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]